The “Heater” of “Cold” Tumors–Blocking IL‐6
Advanced Biology · 2024-07 · 8 (7)
DOI: 10.1002/adbi.202300587 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Biology, online erschienen am 22.05.2024. Verfasst von Weigao Pu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China. Hauptthemen laut MEDLINE: Interleukin-6, Neoplasms, Tumor Microenvironment, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Key Project of Science and Technology in Gansu province, Medical Innovation and Development Project of Lanzhou University.
Abstract (Originalsprache)
The resolution of inflammation is not simply the end of the inflammatory response but rather a complex process that involves various cells, inflammatory factors, and specialized proresolving mediators following the occurrence of inflammation. Once inflammation cannot be cleared by the body, malignant tumors may be induced. Among them, IL‐6, as an immunosuppressive factor, activates a variety of signal transduction pathways and induces tumorigenesis. Monitoring IL‐6 can be used for the diagnosis, efficacy evaluation and prognosis of tumor patients. In terms of treatment, improving the efficacy of targeted and immunotherapy remains a major challenge. Blocking IL‐6 and its mediated signaling pathways can regulate the tumor immune microenvironment and enhance immunotherapy responses by activating immune cells. Even transform “cold” tumors that are difficult to respond to immunotherapy into immunogenic “hot” tumors, acting as a “heater” for “cold” tumors, restarting the tumor immune cycle, and reducing immunotherapy‐related toxic reactions and drug resistance. In clinical practice, the combined application of IL‐6 inhibition with targeted therapy and immunotherapy may produce synergistic results. Nevertheless, additional clinical trials are imperative to further validate the safety and efficacy of this therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China.
- Department of Tumour Surgery, Lanzhou University Second Hospital, Lanzhou, 730030, China.
- General Surgery Department of Lintao County People's Hospital in Gansu Province, Lanzhou, Gansu, 730030, China.
- Gansu Provincial Key Laboratory of Environmental Oncology, Lanzhou, Gansu, 730030, China.
ORCID-Profile: Weidong Zhu
Förderung
- National Natural Science Foundation of China
- Key Project of Science and Technology in Gansu province
- Medical Innovation and Development Project of Lanzhou University
- Gansu Province Innovation Driven Assistance Project
Zitieren
APA
Pu, W., Ma, C., Wang, B., Zhu, W., & Chen, H. (2024). The “Heater” of “Cold” Tumors–Blocking IL‐6. Advanced Biology, 8(7). https://doi.org/10.1002/adbi.202300587
Vancouver
Pu W, Ma C, Wang B, Zhu W, Chen H. The “Heater” of “Cold” Tumors–Blocking IL‐6. Advanced Biology. 2024;8(7). doi:10.1002/adbi.202300587
BibTeX
@article{Pu2024,
author = {Pu, Weigao and Ma, Chenhui and Wang, Bofang and Zhu, Weidong and Chen, Hao},
title = {The “Heater” of “Cold” Tumors–Blocking IL‐6},
journal = {Advanced Biology},
year = {2024},
volume = {8},
number = {7},
doi = {10.1002/adbi.202300587}
}
EUVIMED